Piper Sandler Boosts Zoetis (NYSE:ZTS) Price Target to $205.00

Zoetis (NYSE:ZTS) had its price objective increased by equities researchers at Piper Sandler from $200.00 to $205.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target suggests a potential upside of 22.33% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Finally, StockNews.com downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Trading Up 1.6 %

NYSE ZTS opened at $167.58 on Thursday. Zoetis has a one year low of $144.80 and a one year high of $200.53. The firm has a 50 day simple moving average of $166.30 and a 200-day simple moving average of $177.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a market cap of $75.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Equities research analysts anticipate that Zoetis will post 6.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Zoetis

A number of large investors have recently modified their holdings of ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.